Sangamo Therapeutics, Inc. Common Stock (SGMO)
Sangamo Therapeutics, Inc. (SGMO) is a biotechnology company specializing in gene editing and gene therapy technologies. Founded in 1995, the company focuses on developing genomic medicines to treat and potentially cure genetic diseases, hemophilia, and cell and gene therapy applications. Sangamo utilizes its proprietary zinc finger nuclease (ZFN) platform to engineer precise genomic modifications, aiming to advance innovative treatments across multiple therapeutic areas.
Company News
U.S. stock futures were flat on Tuesday as investors remained cautious ahead of the FOMC meeting. Analysts say the only certainty is that 'things will remain uncertain for the time being'.
The cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders.
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.